drugset / Trial / NCT07276802
The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)
RandomizedCrossoverOpen-labelPrevention
Summary
A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2026-12-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clobetasol | Small molecule | 0.05 % | — |
| Comparator | Fentanyl | Other / unclassified | 1 % | — |
| Comparator | Ketorolac | Other / unclassified | 0.5 % | — |
| Comparator | Moxifloxacin | Small molecule | 0.5 % | — |
| Subject | Nepafenac | Other / unclassified | 0.3 % | — |
| Subject | Triamcinolone | Other / unclassified | 40 mg/ml | — |